GLP-1 Half-Life & Duration: What You Need to Know

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications remain active in your body for different lengths of time depending on the specific drug and route of administration. Injectable semaglutide has a half-life of approximately 7 days, while tirzepatide lasts roughly 5 days, meaning the drug concentration drops by half during these periods.

Understanding GLP-1 duration matters because it directly affects how you experience the medication's appetite-suppressing effects, how quickly you may feel side effects, and how your provider will structure your dosing schedule. At PlexusDx, we emphasize precision wellness—recognizing that metabolism varies significantly among individuals based on genetic and clinical factors.

Understanding GLP-1 Half-Life and Elimination

Half-life is the time required for the body to eliminate half of a medication's active dose. For semaglutide injections, the 7-day half-life means that after one week, approximately 50% of the dose remains in your system. This relatively long half-life enables once-weekly dosing and provides sustained appetite suppression throughout the week.

Tirzepatide, a dual GLP-1/GIP receptor agonist, has a shorter half-life of approximately 5 days but achieves sustained receptor activation through extended tissue binding. Oral formulations of these compounds typically have shorter half-lives due to first-pass hepatic metabolism, requiring more frequent dosing schedules for comparable clinical effect.

Pharmacokinetic Timeline: From Injection to Clearance

After administration, GLP-1 medications follow a predictable timeline of absorption, distribution, and elimination. Peak plasma concentration for injectable semaglutide typically occurs 24-48 hours post-injection, while tirzepatide peaks around 24 hours. Understanding this timeline helps explain when you might notice appetite suppression strongest.

Complete elimination requires approximately 4-5 half-lives, meaning semaglutide clears largely from your system in about 28-35 days, and tirzepatide in roughly 20-25 days. This elimination window matters when switching medications or discontinuing therapy due to side effects.

Medication	Route	Half-Life	Peak Concentration	Approximate Full Clearance
Semaglutide	Injectable (weekly)	~7 days	24-48 hours post-injection	28-35 days
Semaglutide	Oral (daily)	~1-2 hours	1-4 hours post-dose	5-10 days
Tirzepatide	Injectable (weekly)	~5 days	~24 hours post-injection	20-25 days
Tirzepatide	Oral (daily)	~1-2 hours	1-3 hours post-dose	5-10 days

How Individual Metabolism Affects GLP-1 Duration

While published half-lives provide averages, individual clearance rates vary based on age, kidney and liver function, body composition, and genetic variations in metabolic enzymes. Some individuals may experience slower drug clearance, leading to longer symptom duration and potentially increased side effects, while others clear medications more rapidly.

Hepatic metabolism and renal function play critical roles in GLP-1 elimination. Patients with mild to moderate hepatic or renal impairment may experience prolonged drug exposure. Age-related changes in kidney function can also slow clearance, particularly in patients over 65, potentially requiring dose adjustments or longer intervals between administrations.

What Extended Duration Means for Your Treatment Plan

The extended duration of injectable GLP-1s creates both benefits and considerations. Once-weekly dosing improves adherence compared to daily oral medications, and sustained receptor activation produces consistent appetite suppression. However, if you experience intolerable side effects, the medication remains in your system for weeks, requiring patience as your body adjusts.

When discontinuing GLP-1 therapy, appetite and food cravings typically return gradually as drug concentrations fall below effective thresholds. This 3-4 week elimination window means you should plan medication changes with your provider well in advance, not abruptly. Additionally, switching between formulations or agents requires understanding overlap periods to prevent gaps or excessive exposure.

Medical Guidance: Who Should Consider Duration When Dosing

Patients with significant renal impairment, hepatic disease, advanced age, or those taking medications that inhibit GLP-1 metabolism should discuss duration implications with their provider before starting therapy. Similarly, individuals planning surgery or discontinuing therapy should account for the elimination timeline when making decisions with their healthcare team.

If you're considering switching from branded GLP-1 medications to compounded formulations, understanding pharmacokinetics helps ensure continuity of care. Compounded semaglutide and tirzepatide from 503A pharmacies follow the same elimination pathways as branded versions—what differs is sourcing, cost, and provider flexibility in dosing and formulation selection.

How PlexusDx Supports a More Personalized Approach

Genetic variations in metabolic enzymes—particularly those affecting hepatic clearance—may influence how quickly your body eliminates GLP-1 medications. PlexusDx's Precision Peptide Genetic Test examines key variants in peptide signaling pathways that can help provide context around your individual response profile. These insights should be interpreted with a qualified healthcare provider to personalize dosing strategies.

The Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways. While these variants don't predict exact medication clearance rates, they can support a more informed conversation about which GLP-1 agent and dosing frequency might align best with your genetic framework. This is especially valuable when deciding between injectable and oral formulations or when adjusting dose intervals.

Understanding both the pharmacokinetic timeline and your individual genetic context empowers a collaborative discussion with your provider about optimal dosing, timing, and formulation. Whether you're starting compounded semaglutide, tirzepatide, or exploring newer agents, this precision-wellness approach helps ensure your treatment plan accounts for how your body metabolizes and responds to GLP-1 therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What half-life does injectable semaglutide have, and why does that permit weekly dosing?

The article puts the half-life of injectable semaglutide at approximately seven days, meaning roughly half the dose remains after one week. It explains that this unusually long half-life is precisely what enables a once-weekly schedule and sustained appetite suppression across the whole interval, rather than peaks and troughs between doses.

How long does it take for an injectable GLP-1 to leave the body completely?

The article uses the rule that complete elimination takes roughly four to five half-lives. On that basis it puts injectable semaglutide at about 28 to 35 days to clear largely from the system, and injectable tirzepatide at roughly 20 to 25 days. It notes this window matters when switching agents or stopping because of side effects.

When after an injection is the drug concentration highest?

The article puts peak plasma concentration for injectable semaglutide at roughly 24 to 48 hours after the injection, and for injectable tirzepatide at around 24 hours. It uses that timing to explain when appetite suppression is typically felt most strongly during the weekly cycle, and pairs it with the half-life figures to describe the full arc from absorption to clearance.

Why do side effects not stop immediately when someone stops the medication?

Because the drug is still present. The article points out that with an extended-duration injectable, the medication remains in the system for weeks after the last dose, so intolerable side effects require patience while levels fall. It presents this as the flip side of the convenience that once-weekly dosing provides.

Which patient factors slow GLP-1 clearance?

The article names age, kidney and liver function, and body composition as the main variables behind individual differences in clearance. It notes that mild to moderate hepatic or renal impairment may prolong drug exposure, and that age-related decline in kidney function can slow clearance, particularly in patients over 65.

Why should someone planning surgery think about the elimination timeline?

The article groups people planning surgery with those discontinuing therapy, saying both should account for the elimination window when making decisions with their healthcare team. Because a weekly injectable persists for weeks, the drug's effects on gastric emptying do not end with the last dose, which is why it says these changes should be planned well in advance rather than abruptly.

Related Reading

• Can You Get Your Glp 1 Tested
• Genetic Testing 101 What You Need To Know Before Getting Tested
• Maximus Glp 1
• Found Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.